AVTX
Avalo Therapeutics Inc

13,649
Mkt Cap
$296.57M
Volume
741,067.00
52W High
$20.72
52W Low
$3.39
PE Ratio
-1.84
AVTX Fundamentals
Price
$15.38
Prev Close
$16.02
Open
$15.91
50D MA
$15.97
Beta
1.71
Avg. Volume
464,029.88
EPS (Annual)
-$20.91
P/B
3.12
Rev/Employee
$19,173.91
$75.95
Loading...
Loading...
News
all
press releases
Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC
Boothbay Fund Management LLC increased its position in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 1,916.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund...
MarketBeat·15h ago
News Placeholder
More News
News Placeholder
Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX
Cantor Fitzgerald L. P. acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The...
MarketBeat·2d ago
News Placeholder
Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX
Boxer Capital Management LLC bought a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) during the third quarter, according to the company in its most recent filing with the...
MarketBeat·2d ago
News Placeholder
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...
MarketBeat·3d ago
News Placeholder
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
Avalo Therapeutics (NASDAQ:AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa...
MarketBeat·5d ago
News Placeholder
Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday
Avalo Therapeutics (NASDAQ:AVTX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Analysts
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat Ratings...
MarketBeat·8d ago
News Placeholder
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference
Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to...
MarketBeat·12d ago
News Placeholder
RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX
RWA Wealth Partners LLC decreased its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 66.9% in the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·18d ago
News Placeholder
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference
Avalo Therapeutics (NASDAQ:AVTX) Chief Executive Officer Dr. Garry Neil discussed the company's hidradenitis suppurativa (HS) program and upcoming clinical catalyst during a fireside chat at...
MarketBeat·20d ago
<
1
2
...
>

Latest AVTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.